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In accordance with Article 5 of Council Decision 2005/387/JHA on 
the information exchange, risk assessment and control of new 
psychoactive substances 
About this series
EMCDDA–Europol Joint Report publications examine the detailed information 
provided by the EU Member States on individual new psychoactive substances. 
Information is collected from the Reitox network, the Europol National Units and the 
national competent authorities of the European Medicines Agency.
Each Joint Report serves as the basis upon which the decision to conduct a risk 
assessment of the new psychoactive substance is taken. It is part of the three-step 
procedure involving information exchange, risk assessment and decision-making in the 
framework of Council Decision 2005/387/JHA.
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I 1. Introduction
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter 
the ‘Council Decision’) stipulates that ‘Where Europol and the 
EMCDDA, or the Council, acting by a majority of its members, 
consider that the information provided by the Member State 
on a new psychoactive substance merits the collection of 
further information, this information shall be collated and 
presented by Europol and the EMCDDA in the form of a Joint 
Report.’ The Joint Report shall be submitted to the Council of 
the European Union, the European Medicines Agency (EMA) 
and the European Commission.
In March 2017, the EMCDDA and Europol examined the 
available information on the new psychoactive substance 
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
(cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly 
known as ADB-CHMINACA, through a joint assessment based 
upon the following criteria:
1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6. evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information 
collected on ADB-CHMINACA satisfied criteria 1, 4 and 6. The 
two agencies therefore concluded that sufficient information 
had been accumulated to merit the production of a Joint 
Report on ADB-CHMINACA as stipulated by Article 5.1 of the 
Council Decision.
I 2. Information collection process
In compliance with the provisions of the Council Decision, on 
25 April 2017 the EMCDDA and Europol launched a procedure 
for the collection of information on ADB-CHMINACA, in order 
to prepare the Joint Report. The information was collected 
mainly through the Reitox national focal points in the Member 
States, Turkey and Norway as well as the Europol National 
Units. In addition, the EMA collected information through the 
national competent authorities responsible for human and 
veterinary medicinal products in the Member States as well as 
in Norway, Iceland and Liechtenstein. The EMA also provided 
information as relevant to the centralised procedure for 
authorising medicinal products. The information collection 
process was largely concluded by 6 June 2017.
(1) OJ L 127, 20.5.2005, p. 32.
Information collected by Europol
Europol asked the Europol National Units to provide 
information on:
 ¡ the level of production of ADB-CHMINACA in their country;
 ¡ the level of distribution of ADB-CHMINACA in their country;
 ¡ the level of trafficking of ADB-CHMINACA in their country, 
both for internal, transit or export purposes;
 ¡ the number of seizures of ADB-CHMINACA in their country, 
the total amount of the seizures, country of origin, details 
on the physical forms (including photos);
 ¡ the role of organised crime or criminal groups, in the 
production, distribution and trafficking of ADB-CHMINACA 
in their country;
 ¡ any known aspect of violence and/or money laundering 
relating to the production and trafficking of ADB-
CHMINACA.
Europol received responses from 16 Member States (2).
Information collected by the EMA
According to Article 5.3 of the Council Decision, the EMA 
requested that the national competent authorities responsible 
for human and veterinary medicinal products in the Member 
States, Norway, Iceland and Liechtenstein, provide information 
on whether:
 ¡ the new psychoactive substance ADB-CHMINACA has 
obtained a marketing authorisation;
 ¡ the new psychoactive substance ADB-CHMINACA is the 
subject of an application for a marketing authorisation;
 ¡ a marketing authorisation that had been granted in respect 
of the new psychoactive substance ADB-CHMINACA has 
been suspended.
Twenty-three countries provided a response to the EMA’s 
request regarding human and/or veterinary medicinal 
products (3). The EMA also provided information as relevant to 
the centralised procedure for authorising human and 
veterinary medicinal products.
(2) In alphabetical order: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech 
Republic, Estonia, Finland, Germany, Greece, Latvia, Lithuania, Luxembourg, 
Romania, Slovakia and Slovenia.
(3) Austria, Belgium, Denmark, Estonia, Finland, Germany, Greece, Ireland, Latvia, 
Norway, Poland, Spain, Sweden and the United Kingdom provided a response in 
relation to human and veterinary medicinal products. Croatia, Czech Republic, 
Hungary, Italy and the Netherlands provided a response in relation to human 
medicinal products. France, Portugal, Slovakia and Slovenia provided a response 
in relation to veterinary medicinal products.
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Furthermore, in anticipation of Article 7.3 of the Council 
Decision in relation to the manufacturing of medicinal 
products in the European Union, the EMA also requested 
information on whether the new psychoactive substance 
ADB-CHMINACA is used to manufacture a medicinal product:
 ¡ which has been granted a marketing authorisation;
 ¡ for which an application has been made for a marketing 
authorisation; and,
 ¡ for which a marketing authorisation has been suspended 
by a competent authority.
Twenty-three countries (4) provided a response to the EMA’s 
request in this regard. The EMA also provided information as 
relevant to the centralised procedure for authorising human 
and veterinary medicinal products.
Information collected by the EMCDDA
The EMCDDA collected information through:
 ¡ a structured questionnaire to the Reitox national focal 
points. The EMCDDA received replies from 27 Member 
States (5), as well as Turkey and Norway;
 ¡ reports previously provided to the European Union Early 
Warning System, including EMCDDA–Europol Reporting 
Forms and Progress Reports and Final Reports;
 ¡ routine monitoring of open source information;
 ¡ a specific information request to the World Health 
Organization on whether or not ADB-CHMINACA is under 
assessment by the United Nations system; and,
 ¡ a search of open source information conducted specifically 
for the production of the Joint Report which included: 
scientific and medical literature, official reports, grey 
literature, internet drug discussion forums and related 
websites (hereafter, ‘user websites’) and online vendors 
selling ADB-CHMINACA.
Thus, the information included in sections 3.2.1 and 3.3 of the 
Joint Report was provided by Europol, while the EMCDDA 
provided information included in sections 3.1, 3.2.2, 3.4, 3.5, 
3.6, 3.7, 3.8.1, 3.8.2 and 3.8.3 (in part). The information 
included in sections 3.8.3 (in part) and 4 was provided by the 
EMA. Images of the seizures and collected samples reported 
to the EMCDDA are provided in Annex 1.
(4) Austria, Belgium, Denmark, Estonia, Finland, Germany, Greece, Ireland, Latvia, 
Norway, Poland, Spain, Sweden and the United Kingdom provided a response in 
relation to human and veterinary medicinal products. Croatia, Czech Republic, 
Hungary, Italy and the Netherlands provided a response in relation to human 
medicinal products. France, Portugal, Slovakia and Slovenia provided a response 
in relation to veterinary medicinal products.
(5) A reply was not received from Slovakia. 
 3.  Information required by Article 5.2 of 
the Council Decision
The order and titles of subsections 3.1 to 3.8 and section 4, 
below, are as they appear in Article 5.2(a) to (h) and Article 
5.3(a) to (c) of the Council Decision; sections are cross-
referenced with those set down in the Council Decision.
 3.1  Chemical and physical description, including 
the names under which the new psychoactive 
substance is known (Article 5.2(a) of 
the Council Decision)
Chemical description and names
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
(cyclohexylmethyl)-1H-indazole-3-carboxamide carboxamide 
is commonly referred to as ADB-CHMINACA or MAB-
CHMINACA (6).
ADB-CHMINACA is a synthetic cannabinoid receptor agonist. 
It has an indazole core, which is a common structural feature 
in many of the synthetic cannabinoids monitored by the 
EMCDDA.
Two synthetic cannabinoid receptor agonists have been 
recently controlled under Schedule II of the United Nations 
Convention on Psychotropic Substances of 1971: JWH-018 (7) 
and AM-2201 (8). In addition, MDMB-CHMICA, 5F-APINACA 
(5F-AKB48) and XLR-11 will be included in the same schedule.
The molecular structure, molecular formula and molecular 
mass of ADB-CHMINACA are provided in Figure 1.
(6) The common name for the substance is derived after its structural features. 
Different naming systems exist and are used for applying short/code names to 
synthetic cannabinoids.
(7) Naphthalen-1-yl(1-pentyl-1H-indol-3-yl)methanone
(8) 1-(5-Fluoropentyl)-1H-indol-3-yl]-(naphthalen-1-yl)methanone
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ADB-CHMINACA contains a stereocentre thus allowing for the 
existence of a pair of enantiomers, (R)- and (S)-ADB-
CHMINACA. The synthesis of (S)-AB-CHMINACA was first 
described in the patent literature in 2009 (Buchler et al., 
2009). Based on the literature and the most likely precursors 
to be used, an (S)-configuration of the stereocentre could be 
expected.
There is no representative information on the enantiomeric 
composition of the samples of AB-CHMINACA detected within 
the European Union, which in part may reflect the fact that 
stereochemical analysis is not routinely undertaken in forensic 
laboratories. Differentiation of enantiomers is possible using 
the following techniques: chiral chromatography, vibrational 
circular dichroism (VCD) spectroscopy and/or electronic 
circular dichroism (ECD) spectroscopy.
Commonly used names: 
ADB-CHMINACA
Systematic (IUPAC) name: 
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
(cyclohexylmethyl)-1H-indazole-3-carboxamide
Chemical Abstracts names: 
1H- Indazole- 3- carboxamide, N- [(1S) - 1- (aminocarbonyl) - 2, 
2- dimethylpropyl] - 1- (cyclohexylmethyl) - (S enantiomer)
Other chemical names: 
N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-
(cyclohexylmethyl)-1H-indazole-3-carboxamide;
N-(1-carbamoyl-2,2-dimethyl-propyl)-1-(cyclohexylmethyl)
indazole-3-carboxamide;
FIGURE 1 
Molecular structure, molecular formula and molecular mass 
of ADB-CHMINACA
N
N
O
NH
O
NH
2
ADB-CHMINACA
Molecular formula C21H30N4O2
Molecular mass 370.50
N-(1-amino-3,3-dimethyl-1-oxo-2-butanyl)-1-
(cyclohexylmethyl)-1H-indazole-3-carboxamide;
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
(cyclohexylmethyl)-1H-indazole-3-carboxamide;
N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
(cyclohexylmethyl)-1H-indazole-3-carboxamide (S enantiomer);
N-(1-amino-3,3-dimetyl-1-oxobutan-2-yl)-1-(cyklohexylmetyl)-
1H-indazol-3-karboxamid (Swedish)
Other names and code names: 
MAB-CHMINACA
Chemical Abstracts Service (CAS) registry numbers (9): 
1863065-92-2 ADB-CHMINACA racemate 
1185887-13-1 (S)-ADB-CHMINACA
IUPAC International Chemical Identifier Key (InCHI Key) (10): 
ZWCCSIUBHCZKOY-UHFFFAOYSA-N ADB-CHMINACA racemate 
ZWCCSIUBHCZKOY-GOSISDBHSA-N (S)-ADB-CHMINACA
The REACH registered substances database hosted by the 
European Chemicals Agency (ECHA) was searched using the CAS 
registry numbers listed above. The searches returned no hits.
Physical description
In its pure form, ADB-CHMINACA is a white solid (SWGDRUG, 
2016). It is soluble in dichloromethane (DCM), methanol 
(MeOH) and is poorly soluble in water (Slovenian National 
Forensic Laboratory, 2016). It is soluble up to approximately 
1 mg/mL in ethanol, 10 mg/ml in dimethyl sulfoxide (DMSO) 
and 5 mg/ml in dimethyl formamide (DMF) (Cayman Chemical 
Company, 2016a).
The reported melting point for ADB-CHMINACA is 141.5°C 
(SWGDRUG, 2016).
ADB-CHMINACA has been typically seized as a herbal 
material and in powder form. A more detailed description of 
seizures and collected samples can be found in section 3.2.1 
and section 3.2.2.
(9) The Chemical Abstract Service Registry Number (CAS RN) is a unique 
numeric identifier assigned by the Chemical Abstract Service Division of the 
American Chemical Society to a specific, single chemical substance.
(10) InChI Key is a unique, non-proprietary stuctural identifier of chemical 
substances useful in electronic sources.
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Chemical stability and typical reactions
For long term storage it is recommended that ADB-
CHMINACA, supplied as a solid, is stored at -20ºC (Cayman 
Chemical Company, 2016b).
Detection and analysis
Methods documented in the literature for the detection of 
ADB-CHMINACA include: gas chromatography–mass 
spectrometry (GC-MS), high performance liquid 
chromatography time-of-flight (HPLC-TOF), Fourier transform 
infrared spectroscopy attenuated total reflectance (FTIR-ATR) 
and gas chromatography–mass spectrometry– infrared 
(GC-MS-IR) condensed phase, ion chromatography (IC) and 
nuclear magnetic resonance spectroscopy (NMR) (Slovenian 
National Forensic Laboratory, 2016) (11).
In addition, the analytical profile of ADB-CHMINACA using gas 
chromatography–mass spectrometry (GC-MS) (Akamatsu et 
al., 2015 and Wurita et al., 2015), liquid chromatography–
mass spectrometry (LC-MS) (Akamatsu et al., 2015), liquid 
chromatography tandem mass spectrometry (LC-MS-MS) 
(Hasegawa et al., 2015 and Wurita et al., 2015) and nuclear 
magnetic resonance (NMR) (Buchler et al., 2009) has been 
described in the literature.
Quantification of ADB-CHMINACA in products can be carried 
out according to the general procedure described by the 
UNODC (UNODC, 2013).
 3.2  Information on the frequency, circumstances 
and/or quantities in which a new psychoactive 
substance is encountered, and information on the 
means and methods of manufacture of the new 
psychoactive substance (Article 5.2(b) of the 
Council Decision)
The data reported to Europol discussed in section 3.2.1 may 
overlap with the data reported to the EMCDDA discussed in 
section 3.2.2.
3.2.1 Information provided to Europol
Europol received replies from 16 Member States (Austria, 
Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, 
Finland, Germany, Greece, Latvia, Lithuania, Luxembourg, 
Romania, Slovakia and Slovenia).
(11) An impurity (possibly cyclohexylmethyl) was also found. 
Eight countries reported that they have no available 
information on ADB-CHMINACA (Austria, Belgium, Croatia, 
Cyprus, Czech Republic, Greece, Luxembourg and Slovakia).
Eight countries provided information on ADB-CHMINACA 
(Bulgaria, Estonia, Finland, Germany, Latvia, Lithuania, 
Romania and Slovenia).
The level of production
No information was received in relation to the production of 
ADB-CHMINACA.
The level of distribution
At least 120 seizures were reported by seven Member States: 
Bulgaria (2), Estonia (1), Finland (exact number unspecified), 
Germany (95), Latvia (17), Lithuania (1) and Romania (2).
 ¡ Bulgaria: two seizures, one of which was a crystalline 
substance in a bag, amounting to 9 g, in postal package 
from Spain to Bulgaria, labelled ‘MMB CHMINACA’; and one 
seizure made in 2016.
 ¡ Estonia: 1 courier seizure made in 2017, amounting to 
203 g, which came from Russia.
 ¡ Finland: unspecified number of seizures made in 2015 and 
2016.
 ¡ Germany: 70 seizures made in 2016 which amounted to 
2.1 kg, most of which were in the form of herbal material 
(‘legal high’ products). One of the seizures amounted to 
1.66 kg; 25 seizures in 2017 which amounted to 85 g, most 
of which were in powder form.
 ¡ Latvia: 11 seizures of herbal material in 2015 and 6 seizures 
in 2016, which amounted to 528 g and 5.4 g, respectively.
 ¡ Lithuania: 1 seizure containing also AD-FUBINACA, which 
amounted to 0.3 g.
 ¡ Romania: 2 seizures in 2015, amounting to 467 g and 871 g.
The level of trafficking
Information related to trafficking routes is limited to the 
seizures reported above.
3.2.2 Information provided to the EMCDDA
The EMCDDA received responses from 27 Member States (5), 
as well as from Turkey and Norway. Of these, 17 Member States 
(Belgium, Croatia, Estonia, Finland, France, Germany, Greece, 
Hungary, Latvia, Lithuania, the Netherlands, Poland, Romania, 
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Slovenia, Spain, Sweden and the United Kingdom), Turkey and 
Norway reported detections of ADB-CHMINACA (12).
It is important to note that detections of ADB-CHMINACA may 
be under-reported since the substance is not routinely 
screened for. Three Member States (Austria, Slovenia and 
Sweden) reported that ADB-CHMINACA is part of routine 
screening in some (but not all) of their laboratories.
Seizures
In total, 3 794 seizures of ADB-CHMINACA were reported to 
the EMCDDA by 17 Member States, Norway and Turkey: 
Belgium (16), Croatia (2), Estonia (2), Finland (10), France (3), 
Germany (2), Greece (1), Hungary (75), Latvia (33), Lithuania 
(1), the Netherlands (1), Norway (2), Poland (233), Romania 
(1), Slovenia (1), Spain (1), Sweden (83), Turkey (3162) and the 
United Kingdom (165). The majority of the seizures comprise 
police and customs cases, with additional seizures taking 
place in custodial settings.
Seizures included herbal materials, powders, blotters and 
other physical forms. A summary is provided below.
Herbal material
 ¡ 485 seizures of ADB-CHMINACA in herbal material were 
reported by 13 countries: Croatia, Estonia, Germany, 
Greece, Hungary, Latvia, Lithuania, Norway, Poland, 
Romania, Slovenia, Sweden and the United Kingdom, 
amounting to nearly 11 kg seized. In addition, Turkey 
reported around 3 160 seizures of herbal material 
amounting to almost 128 kg which have not been included 
in the total count (13).
 ¡ The largest single seizure of ADB-CHMINACA in herbal 
material was reported by Germany, amounting to 1.66 kg of 
a mixture containing ADB-CHMINACA, 5F-AMB-PICA, 
EMB-FUBINACA, 5F-APP-PINACA, THC and CBD. Greece 
reported a seizure of nine bags of herbal material, found to 
contain just over 1 kg of ADB-CHMINACA mixed with 
5F-AMB. The seizure was made during a raid on a tobacco 
store in Drama, where a number of products containing 
other synthetic cannabinoids were seized.
In herbal material, ADB-CHMINACA was commonly found 
mixed with other synthetic cannabinoids (33 % of the cases).
(12) ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples that are analytically confirmed. Seizure 
means a substance available (seized) through law enforcement activities (police, 
customs, border guards, etc.). Collected samples are those that are actively 
collected by drug monitoring systems (such as test purchases) for monitoring 
and research purposes. Biological samples are those from human body fluids 
(urine, blood, etc.) and/or specimens (tissues, hair, etc.). 
(13) Minimum estimate provided by the Turkish national focal point for 2016.
Powder
 ¡ 76 seizures of powders were reported by 10 countries: 
Belgium, Finland, France, Hungary, Latvia, the Netherlands, 
Poland, Spain, Sweden and Turkey, amounting to a total of 
9.8 kg.
 ¡ The largest single seizure of ADB-CHMINACA in powder 
form was reported by Belgium (3 kg seized by customs, 
originating in China, destined for Austria and Romania).
 ¡ Turkey reported 2 large seizures of powders: 1.84 kg, 
containing ADB-CHMINACA, FUBIMINA, FUB-AKB, 
AMB-FUBINACA and NEP; 1 kg containing ADB-CHMINACA 
mixed with THC, cannabinol and cannabidiol.
 ¡ In 92 % of the cases of seized powders, ADB-CHMINACA 
was the only substance reported.
Other physical forms
 ¡ Seizures of blotters containing ADB-CHMINACA were 
reported by Poland (40 cases; 25.35 g) and Sweden 
(1 case; 2 blotters).
 ¡ Poland reported 19 seizures of ‘agglomerated material’ 
containing ADB-CHMINACA mixed with either caffeine 
(14 cases) or 5F-AKB48 (5), amounting to a total of over 
235 g of substance.
 ¡ One seizure of a ‘slab’ containing ADB-CHMINACA mixed 
with MDMB-CHMICA was reported by Estonia (13.42 g); 
1 case of a ‘lump’ containing ADB-CHMINACA, AB-
FUBINACA, 5F-ADB-PINACA and FUB-APINACA was 
reported by Norway (9.7 g) and one seizure of a ‘paste-like 
substance’ was reported by Finland (0.7 g).
No quantitative information on purity was provided to the 
EMCDDA.
Collected samples
Two collected samples of ADB-CHMINACA were reported to 
the EMCDDA: by Slovenia (5 g of white powder purchased 
online as ‘5F-AEB’ from China) and Germany (one of many 
substances identified in a number of powder samples 
collected from a scene of a death).
Biological samples
Serious adverse events with confirmed exposure to ADB-
CHMINACA from biological samples are discussed in 
section 3.4.2.
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In addition to these, 28 detections where ADB-CHMINACA 
was analytically confirmed in biological samples were 
reported by two Member States: Hungary (22 cases) and 
Poland (6) (14). Detections include:
 ¡ 22 cases were reported in relation to drug abuse 
(consumption), intoxication or non-fatal intoxication, with 
no further details provided.
 ¡ six cases related to persons suspected of driving under the 
influence of drugs, all reported by Hungary.
 3.3  Information on the involvement of organised 
crime in the manufacture or trafficking of the new 
psychoactive substance (Article 5.2(c) of the 
Council Decision)
No information concerning the involvement of organised crime 
in the manufacture and/or trafficking of the ADB-CHMINACA 
was provided.
Money laundering aspects
No information was received on money laundering in 
connection with the production and/or trafficking of ADB-
CHMINACA.
Violence in connection with production,  
wholesale and distribution
No information was received on incidents of violence in 
connection with the production, wholesale and/or trafficking 
of ADB-CHMINACA.
 3.4  A first indication of the risks associated with the 
new psychoactive substance, including the health 
and social risks, and of the characteristics of 
users — Article 5.2(d) of the Council Decision
3.4.1 Health risks
Pharmacology and toxicology
Limited data suggests that ADB-CHMINACA is a CB
1
 receptor 
agonist (US DEA, 2015 (15)) that shares some similarities with 
the major psychoactive constituent of cannabis (–)-trans-Δ9-
tetrahydrocannabinol (THC) and synthetic cannabinoids such 
as JWH-018 and MDMB-CHMICA (EMCDDA, 2017; Järbe and 
Raghav, 2017; Pertwee, 2014; Reggio, 2009).
(14) In addition, Turkey reported 181 samples (blood, hair and urine) which may 
contain duplicates and therefore have not been included in the total count. 
(15) Enantiomeric composition not specified.
The acute effects of THC (and consequently cannabis) include: 
relaxation, euphoria, lethargy, depersonalisation, distorted 
perception of time, impaired motor performance, 
hallucinations, paranoia, confusion, fear, anxiety, dry mouth, 
reddening of the conjunctivae of the eyes, tachycardia, nausea 
and vomiting. THC also has an abuse liability and dependence 
potential (Pertwee, 2014; Wiley et al., 2016). Similar effects to 
cannabis have been reported for synthetic cannabinoids such 
as ADB-CHMINACA. In some cases, the effects are reported 
to be more pronounced/severe (EMCDDA, 2017).
Compared to cannabis, severe and fatal poisoning appears to 
be more common with synthetic cannabinoids (EMCDDA, 
2017; Tait et al., 2016). Poisoning may include rapid loss of 
consciousness/coma, cardiovascular effects (such as 
hypertension, tachycardia, bradycardia, chest pain, myocardial 
infarction and stroke), seizures and convulsions, vomiting/
hyperemesis, delirium, agitation, psychosis, aggressive and 
violent behaviour. Sudden death has also been reported. The 
mechanisms of this toxicity are poorly understood (Tai and 
Fantegrossi, 2016), but factors that are likely to play an 
important role are the potency of the substances and the 
doses that users are exposed to. In addition, some of the 
effects of poisoning — such as loss of consciousness or 
behavioural effects — may place users at additional risks such 
as choking on vomitus, drowning or self-harm.
There is no antidote to poisoning caused by synthetic 
cannabinoids.
In general, the use of herbal smoking mixtures containing 
synthetic cannabinoids appears to pose a high risk of 
poisoning. This is because manufacturers guess the amount 
of cannabinoids(s) to add to the herbal material and the 
manufacturing process makes it difficult to dilute them 
sufficiently and distribute them consistently throughout the 
material. This can result in mixtures that contain a large 
amount of highly potent cannabinoid, as well as ‘hot pockets’ 
where the cannabinoid is highly concentrated within parts of 
the herbal material (e.g. Schäper et al., 2016). Together, this 
makes it difficult for users to control the dose that they are 
exposed to. As these mixtures are typically smoked as 
cigarettes (‘joints’), users can inadvertently administer 
a toxic dose; in some cases, a small number of puffs from 
a cigarette have been sufficient to cause severe poisoning. 
Reflecting these risks, smoking mixtures have caused 
a large number of outbreaks of mass poisonings in recent 
years (Adams et al., 2017; Kasper et al., 2015; Schwartz et 
al., 2015; Shevyrin et al., 2015; Trecki et al., 2015; Tyndall et 
al., 2015).
While there is no specific data for ADB-CHMINACA, the 
chronic health risks might share similarities to cannabis and 
other synthetic cannabinoids. This may include dependence.
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3.4.2 Serious adverse events
Acute intoxications
A total of three acute intoxications with confirmed exposure to 
ADB-CHMINACA were reported by the United Kingdom (16). 
The cases occurred during 2016. In one case, no other 
substances were detected. In the remaining two cases, 
another synthetic cannabinoid was detected. All the cases 
included clinical features of poisoning similar to those 
reported for synthetic cannabinoids.
Deaths
A total of 12 deaths with confirmed exposure to ADB-
CHMINACA were reported by Germany (6 cases), Hungary (1) 
and Sweden (5). The cases occurred between 2014 and 2016.
All the deaths were male. They were aged between 17 and 
38 years (mean 27.8, median 27.5). In one case, no other 
substances were detected. In the remaining cases, other 
substances were detected including central nervous system 
depressants (such as alcohol and synthetic cannabinoids). 
Where known, many of the cases were found dead and 
typically in a home environment. In at least nine cases, 
ADB-CHMINACA was the cause of death or contributed to the 
death.
3.4.3 Characteristics of users
Similar to other synthetic cannabinoids, ADB-CHMINACA is 
sold and used as a ‘legal’ substitute for cannabis (EMCDDA, 
2009; EMCDDA, 2017). The most common way of using it is by 
smoking a cigarette of herbal mixture that has been laced with 
the substance. Because these products rarely state the 
ingredients, most users will be unaware that they are using 
ADB-CHMINACA.
People who use ADB-CHMINACA may include recreational 
users, high-risk drug users and groups who experiment with 
the substance (such as psychonauts). This may also include 
individuals who are subject to drug testing (such as people in 
drug treatment, prisoners and drivers) because some drug 
tests/screens will be unable to detect ADB-CHMINACA. In the 
past few years, synthetic cannabinoids have become 
increasingly used by vulnerable groups (such as the homeless 
and prisoners).
(16) In addition, Germany reported eight acute intoxications with possible 
exposure to ADB-CHMINACA and Sweden reported two acute intoxications with 
suspected exposure to ADB-CHMINACA. These cases are not discussed further 
in this report.
3.4.4 Social risks
While there is limited data for ADB-CHMINACA, the social 
risks might share some similarities with cannabis and other 
synthetic cannabinoids.
Of particular note is that synthetic cannabinoids are 
increasingly used by vulnerable groups, such as the homeless 
and prisoners. Reports suggest that this has caused new 
health and social problems as well as exacerbated existing 
ones for these groups. For example, in prisons, alongside the 
adverse health effects, the market in synthetic cannabinoids 
has been linked to an increase in aggression, violence, bullying 
and debt. In some cases this has caused a serious threat to 
the overall safety and security of the prison environment 
(Blackman et al., 2017; HMIP, 2015; Ralphs et al., 2017; 
User Voice, 2016).
 3.5  Information on whether or not the new substance 
is currently under assessment, or has been under 
assessment, by the UN system (Article 5.2(e) of 
the Council Decision)
The World Health Organization is the specialised United 
Nations agency designated for the evaluation of the medical, 
scientific and public health aspects of psychoactive 
substances under the Single Convention on Narcotic Drugs, 
1961 and the Convention on Psychotropic Substances, 1971.
On 1 May 2017, the World Health Organization informed the 
EMCDDA that ADB-CHMINACA is currently not under 
assessment and has not been under assessment by the UN 
system.
 3.6  The date of notification on the Reporting Form of 
the new psychoactive substance to the EMCDDA 
or to Europol (Article 5.2(f) of the Council 
Decision)
The first official EMCDDA–Europol notification of ADB-
CHMINACA dates from 12 September 2014 from the 
Hungarian national focal point. The Reporting Form details 
a seizure of 2.07 g of light brown powder that was seized in 
August 2014 by the Hungarian Police in Hajós. The substance 
was analytically confirmed by GC-MS, FT-IR and NMR.
ADB-CHMINACA was added to the list of new psychoactive 
substances monitored by the EMCDDA and Europol through 
the European Union Early Warning System. A profile of the 
substance was created on the European Database on New 
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Drugs (EDND). Since then, analytical details and other 
information, including a public health alert, have been 
exchanged between the EMCDDA, Europol, the Member 
States, Turkey and Norway, on an ad hoc basis; the European 
Commission and the EMA have been kept duly informed.
 3.7  Information on whether or not the new 
psychoactive substance is already subject to 
control measures at national level in a Member 
State (Article 5.2(g) of the Council Decision)
Thirteen Member States (Belgium, Croatia, Cyprus, Czech 
Republic, Estonia, Finland, France, Germany, Italy, Latvia, 
Lithuania, Luxembourg and Sweden) reported that ADB-
CHMINACA is controlled under drug control legislation.
Three Member States (Austria, Hungary and Poland) and 
Turkey reported that ADB-CHMINACA is controlled under 
specific new psychoactive substances control legislation.
Norway reported that ADB-CHMINACA is controlled under 
medicinal products legislation.
Eleven Member States (Bulgaria, Denmark, Greece, Ireland, 
Malta, the Netherlands, Portugal, Romania, Slovenia, Spain 
and the United Kingdom) reported that ADB-CHMINACA is not 
subject to control measures at the national level.
Slovakia did not provide information on the control status of 
ADB-CHMINACA.
 3.8  Further information (Article 5.2(h) of the 
Council Decision)
3.8.1  The chemical precursors that are known to have 
been used for the manufacture of the substance
No information was reported by the Member States, Turkey or 
Norway, about the chemical precursors or manufacturing 
methods used to make the ADB-CHMINACA which has been 
detected within Europe.
The synthesis of ADB-CHMINACA was first described in 
a 2009 patent (Buchler et al., 2009). The starting compound 
methyl 1H-indazole-3-carboxylate used in the 2009 patent, 
which is commercially available, can be prepared from 
1H-indole-2,3-dione using the procedure of Johnson et al. 
(Johnson et al., 2005).
Possible synthetic routes for the production of ADB-
CHMINACA could utilise L-tert-leucinamide (for the synthesis 
of the (S) enantiomer), 1H-indole-3-carboxylic acid and methyl 
1H-indazole-3-carboxylate as potential precursors.
3.8.2  The mode and scope of the established or 
expected use of the new substance
No studies were identified that have examined the mode and 
scope of established or expected use of ADB-CHMINACA. 
Given the limited information currently available, the relevant 
information has been included in the previous sections.
3.8.3  Other use of the new psychoactive substance 
and the extent of such use, the risks associated 
with this use of the new psychoactive 
substance, including the health and social risks
No information was provided by the Member States, Turkey or 
Norway that indicated that ADB-CHMINACA had any other use 
apart from in analytical reference materials and scientific 
research.
From the available information, it does not appear that 
ADB-CHMINACA is used in the manufacture of a medicinal 
product in the European Union. However, the data collection is 
incomplete and some countries indicated that this information 
is not known. It is understood that the collection of such 
information is a challenge in the absence of a database on the 
synthetic route of all medicinal products.
Eleven countries (Austria, Belgium, Croatia, Denmark, Finland, 
Greece, Italy, the Netherlands, Poland, Spain and the United 
Kingdom) reported that ADB-CHMINACA is not used to 
manufacture a medicinal product for human use. Eight 
countries (Czech Republic, Estonia, Germany, Hungary, 
Ireland, Latvia, Norway and Sweden) reported that it was 
unknown if ADB-CHMINACA is used to manufacture 
a medicinal product for human use.
In addition, the EMA reported that it is not known if ADB-
CHMINACA is used in the manufacture of medicinal products 
for human use and which are centrally authorised within the 
European Union.
Eleven countries (Austria, Belgium, Denmark, Finland, France, 
Greece, Latvia, Poland, Slovakia, Spain and the United 
Kingdom) provided information that ADB-CHMINACA is not 
used to manufacture a medicinal product for veterinary use. 
Seven countries (Estonia, Germany, Ireland, Norway, Portugal, 
Slovenia and Sweden) reported that it was unknown if 
11 / 15
JOINT REPORTS I ADB-CHMINACA
ADB-CHMINACA is used to manufacture a medicinal product 
for veterinary use.
In addition, the EMA reported that it is not known if ADB-
CHMINACA is used in the manufacture of medicinal products 
for veterinary use and which are centrally authorised within 
the European Union.
 4.  Information from the EMA (Article 5.3 
of the Council Decision)
Nineteen countries (Austria, Belgium, Croatia, Czech Republic, 
Denmark, Estonia, Finland, Germany, Greece, Hungary, 
Ireland, Italy, Latvia, the Netherlands, Norway, Poland, Spain, 
Sweden and the United Kingdom) reported that:
 ¡ ADB-CHMINACA has not been granted a marketing 
authorisation as a medicinal product for human use;
 ¡ ADB-CHMINACA is not the subject of an application for 
a marketing authorisation as a medicinal product for human 
use;
 ¡ there had been no cases of suspended marketing 
authorisation in respect to ADB-CHMINACA as a human 
medicine.
Eighteen countries (Austria, Belgium, Denmark, Estonia, 
Finland, France, Germany, Greece, Ireland, Latvia, Norway, 
Poland, Portugal, Slovakia, Slovenia, Spain, Sweden and the 
United Kingdom) reported that:
 ¡ ADB-CHMINACA has not been granted a marketing 
authorisation as a medicinal product for veterinary use;
 ¡ ADB-CHMINACA is not the subject of an application for 
a marketing authorisation as a medicinal product for 
veterinary use;
 ¡ there had been no cases of suspended marketing 
authorisation in respect to ADB-CHMINACA as a veterinary 
medicine.
The EMA also reported that ADB-CHMINACA:
 ¡ has not been granted a marketing authorisation as 
a medicinal product for neither human nor veterinary use 
through the centralised procedure;
 ¡ is not the subject of an application for a marketing 
authorisation for neither human nor veterinary use through 
the centralised procedure;
 ¡ is not the subject of a suspended marketing authorisation 
for neither human nor veterinary use through the 
centralised procedure.
I 5. Conclusion
ADB-CHMINACA is a synthetic cannabinoid and a CB
1
 
receptor agonist. It shares some pharmacological similarities 
with Δ9-tetrahydrocannabinol (THC), which is responsible for 
the major psychoactive effects of cannabis. In humans, 
ADB-CHMINACA appears to cause effects that resemble 
those of cannabis and other synthetic cannabinoids.
ADB-CHMINACA has been available in the European Union 
since at least August 2014 and has been detected in 
18 Member States, Turkey and Norway. More than 
600 seizures have been made within the European Union, 
which includes 7 kg of powder and 11 kg of herbal material 
which has been laced with ADB-CHMINACA. This herbal 
material is typically sold as smoking mixtures; the products 
are marketed as ‘legal’ replacements to cannabis. Due to the 
way that these products are produced, it appears that users 
are at risk of serious poisoning. There are indications that the 
AB-CHMINACA available on the market was synthesised by 
chemical companies based in China.
Twelve deaths with confirmed exposure to ADB-CHMINACA 
have been reported by three Member States. In at least nine of 
the deaths, ADB-CHMINACA was the cause of death or 
contributed to the death.
ADB-CHMINACA is currently not under assessment and has 
not been under assessment by the UN system. ADB-
CHMINACA is not subject to control measures in 11 Member 
States.
We conclude that the health and social risks caused by the 
manufacture, trafficking and use of ADB-CHMINACA and the 
involvement of organised crime and possible consequences of 
control measures, could be thoroughly assessed through 
a risk assessment procedure in accordance with Article 6 of 
Council Decision 2005/387/JHA.
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